- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectively deliver molecules across the blood-brain barrier - ABL Bio to receive up to £77 million in...
Read More Details
Finally We wish PressBee provided you with enough information of ( ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases )
Also on site :
- Rock Legend Shares Bold Message About L.A. Protests
- Tony Awards draw best audience in 6 years for CBS
- Ax-wielding man at Pacific Beach library faces preliminary hearing